Biopure Case

In regard to this topic, among all of the case studies assigned by Dr. Mena, the case about Biopure Corp stood out as a significant example of overestimating some aspects of the strategic planning that led to the failure of the business. Biopure Corp had spent million of dollars on research and development to create two versions of blood substitute for human and animal called Hemopure and Oxyglobin. During the strategic planning process, Biopure was optimistic with both Hemopure and Oxyglobin because of Oxyglobin high acceptance rate among the consumers for a market research survey and it was already approved for release by the FDA. However, the company made a fatal mistake of underestimating the government regulation and strategic uncertainty